Skip to main content

5 Result(s)

within A. G. Harris Remove this filter Neurosciences Remove this filter

and

  1. No Access

    Article

    Reduction in sella turcica volume

    Ten patients with acromegaly were treated with the long-acting somatostatin analogue, Sandostatin (SMS 201-995, octreotide) for more than one year. Computerized tomography was performed before and on 4 differe...

    E. Lund, J. Jørgensen, S. E. Christensen, J. Weeke, H. Ørskov… in Neuroradiology (1991)

  2. No Access

    Chapter and Conference Paper

    Effects of Long-Term Administration of Sandostatin® (SMS 201–995) at Increasing Doses in 40 Acromegalic Patients. Results from the French Sandostatin Acromegaly Study Group

    Several studies demonstrate the efficacy of short- and long-term Sandostatin® treatment in acromegaly administered subcutaneously at doses ranging from 150 to 300 µg up to 600 µg per day [1, 3, 5, 7–10]. A rhythm...

    G. Sassolas, P. Fossati, P. Chanson… in Sandostatin® in the Treatment of Acromegaly (1988)

  3. No Access

    Chapter and Conference Paper

    Observations During a Clinical Trial of Sandostatin® in Acromegalic Patients

    Ten acromegalic patients were studied over a period of 75 weeks. Four had had one or more attempted ablations of their pituitary adenoma, six were previously untreated or had been unsuccessfully treated with b...

    H. Ørskov, J. Weeke, S. E. Christensen… in Sandostatin® in the Treatment of Acromegaly (1988)

  4. No Access

    Chapter and Conference Paper

    Long-Term Treatment of Acromegaly by Continuous Subcutaneous Infusion of the Long-Acting Somatostatin Analog Sandostatin® (SMS 201–995, Octreotide)

    Recently the long-acting somatostatin analog Sandostatin® (SMS 201–995, Octreotide) was introduced for the therapy of acromegaly. On a two or three daily subcutaneous (s.c.) injection regimen plasma GH levels hav...

    J. P. Tauber, Th. Babin, M. C. R. Ducasse… in Sandostatin® in the Treatment of Acromegaly (1988)

  5. No Access

    Chapter and Conference Paper

    Long-Term Efficacy of Sandostatin®(SMS 201–995, Octreotide) in 178 Acromegalic Patients. Results from the International Multicentre Acromegaly Study Group

    Sandostatin® (SMS 201–995), a synthetic long-acting octapeptide, represents an efficacious alternative therapeutic candidate to available treatment modalities for acromegaly.

    A. G. Harris, H. Prestele, K. Herold… in Sandostatin® in the Treatment of Acromegaly (1988)